A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis

NCT00255424 Phase 3 COMPLETED

The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.

Details

Lead sponsor	AMAG Pharmaceuticals, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	304
Start date	2004-05
Completion	2006-08

Conditions

• Anemia

Interventions

• ferumoxytol or oral iron

Primary outcomes

• The mean change in hemoglobin from baseline.

Countries

United States